---
title: "PRP Therapy For Musculoskeletal Injuries: A Primer"
description: "A clinical primer on PRP in musculoskeletal care. Preparation variables, injection targets, the evidence base and where the open questions still sit."
url: "https://regenmedacademy.com/prp-therapy-for-musculoskeletal-injuries/"
---

# PRP therapy for musculoskeletal injuries: what every clinician should know

- [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/)
- June 1, 2026

![Clinician performing an ultrasound-guided knee injection with the probe and syringe in hand and the ultrasound image on a monitor](https://regenmedacademy.com/wp-content/uploads/2026/09/PRP-therapy-for-musculoskeletal-injuries_-what-every-clinician-should-know-r3.webp)

*Written by [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/), founder of Regen Med Academy. Oscar is not a clinician. This post is education for licensed providers and is not medical advice. Last updated November 4, 2026.*

Platelet-rich plasma (PRP) has become one of the most discussed topics in musculoskeletal medicine, yet many clinicians still lack a clear picture of what the evidence actually supports. This guide breaks down the science, regulatory status, condition-by-condition evidence, safety profile, and patient selection criteria so you can make informed decisions about whether PRP fits your clinical practice.

**Summary:** PRP preparation devices are FDA cleared for use with bone graft material. Injecting PRP into joints, tendons, ligaments or other soft tissue is off-label. The evidence differs by condition, and the sources disagree: a 2024 European consensus supports PRP for mild to moderate knee OA, while the [2026 ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf) strongly recommends against PRP for knee and hip OA. Preparation methods vary widely across studies. Read on for the regulatory status, what named studies report and where they stop, and how to counsel patients.

Some providers who come to us describe the same problem: what was sold to them as training was a product pitch. This post is the evidence side of that conversation. It sets out what named sources report about PRP for musculoskeletal use, with links to the sources, so you can read them yourself.

The reality is that PRP occupies a unique space in musculoskeletal medicine. It has genuine biological plausibility, a growing body of meta-analytic evidence, and real clinical adoption. It also has significant preparation variability, conflicting guideline recommendations, and important regulatory distinctions that many clinicians misunderstand. Getting the facts right matters because misinformation in this space can waste patient money, delay effective care, create regulatory exposure, and damage your professional credibility.

**Important Disclaimer**

Regenerative Medicine Academy (RMA) is an education company providing training for licensed clinicians. This article is educational content and does not constitute medical advice, legal counsel, or a guarantee of clinical outcomes. Every PRP injection use discussed here is an off-label use of a device that FDA cleared for use with bone graft material, and these uses are subject to state and federal regulations. Clinicians are responsible for understanding FDA regulatory status, scope of practice, informed consent, and malpractice implications before implementing any technique in practice. Individual clinical judgment and patient-specific factors must guide all clinical decisions.

## **What is PRP and how does it work?**

Platelet-rich plasma is an autologous blood product, meaning it comes from the patient’s own blood. A clinician draws a small sample of venous blood and processes it through a centrifuge. The centrifuge separates red blood cells from a concentrated layer of platelets and plasma. The result is a preparation with platelet concentrations typically several times higher than normal whole blood.

The rationale for PRP rests on growth factors. PRP contains growth factors from platelets and from the plasma. Commonly named ones include platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1).

That is a rationale, not evidence of a clinical effect. Whether PRP changes anything in a given tissue, in a given patient, is a question for clinical trials, and the trials summarized below do not agree. Every musculoskeletal injection use of PRP is off-label.

PRP is a mix of many proteins and cells, and different preparation systems make different products. Trial results differ by tissue, preparation and patient, which is one reason to record the preparation you use for every patient.

## **PRP is more than LP versus LR: leukocyte subtypes and platelet dose**

The most common way clinicians categorize PRP is by leukocyte content: leukocyte-poor PRP (LP-PRP) versus leukocyte-rich PRP (LR-PRP). This binary framing is useful as a starting point, but the underlying biology is more nuanced. Two issues are worth understanding in detail: the type of leukocytes actually present in the preparation, and the total platelet dose delivered to the tissue.

Two subtypes of one product: the head-to-head data overlap more than the marketing suggests.

### **The leukocyte question is really about subtypes**

This is the question I hear, in my own words: “Doctors ask me all the time, is it leukocyte-rich or leukocyte-poor PRP? Well, first of all, which leukocytes are you talking about?”

White blood cells are not a single category. They include five main types: neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Each plays a different role in immunity and healing.

Centrifugation does not concentrate all five types equally. A [2023 study of 335 knee OA patients](https://pubmed.ncbi.nlm.nih.gov/37090378/) (Turajane et al., Cureus) found that the PRP prepared in that study had roughly double the lymphocyte ratio of whole blood and about half the neutrophil ratio. That finding describes that study’s preparation. Other preparation systems may differ.

The roles of each white cell type in an injected preparation are not settled. Which white cells a preparation contains, and in what share, is one more variable to know and record.

Which preparation suits which use is not settled. Consensus statements and trials do not agree on one answer, so choose a preparation on purpose and record it. In the head-to-head randomized trial comparing LP-PRP and LR-PRP for knee OA ([Di Martino et al., 192 patients](https://pubmed.ncbi.nlm.nih.gov/35103547/)), the two showed no significant difference at 12 months on standard outcome measures.

### **The platelet dose debate**

Marketing claims often state that PRP requires 10 billion platelets to be effective. This figure traces back primarily to a [single 2021 RCT by Bansal and colleagues](https://pubmed.ncbi.nlm.nih.gov/33597586/), published in Scientific Reports. That study tested one dose level rather than comparing multiple doses head-to-head, so the “10 billion threshold” is an inference from one dose group rather than a finding from a dose-finding trial. Only a small number of studies directly support this specific number.

The broader dose-response literature points to a different picture. A [2025 systematic review by Berrigan and colleagues](https://pubmed.ncbi.nlm.nih.gov/38513880/), published in Arthroscopy, analyzed 31 PRP arms across knee OA RCTs. Positive-outcome arms averaged about 5.5 billion platelets per injection, while no-difference arms averaged about 2.3 billion. The authors concluded that improved outcomes may be related to a greater platelet dose.

A [2024 randomized trial by Patel and colleagues](https://pubmed.ncbi.nlm.nih.gov/38410168/), published in Orthopaedic Journal of Sports Medicine, directly compared an 8 mL “superdose” (about 5.65 billion platelets) to a 4 mL conventional dose (about 2.82 billion). The higher dose produced significantly better WOMAC and KOOS scores, two standard knee pain and function questionnaires. A placebo-controlled trial found no difference. In the [2021 RESTORE trial by Bennell and colleagues](https://research.monash.edu/en/publications/effect-of-intra-articular-platelet-rich-plasma-vs-placebo-injecti/), published in JAMA, 288 patients with mild to moderate knee OA were randomized to PRP or saline placebo injections, and PRP “did not result in a significant difference in symptoms or joint structure at 12 months.”

There is also evidence that more is not always better. A [2026 meta-analysis by Hooper and colleagues](https://pubmed.ncbi.nlm.nih.gov/40980837/), published in PM&R, classified knee OA PRP doses as low (1-5 billion), moderate (5-10 billion), and high (over 10 billion). In that analysis, moderate-dose arms showed the greatest functional improvement, and high-dose arms showed less pain reduction at 6 months than arms in the 1 to 10 billion range. These are associations across pooled trials, not a target dose.

No professional society names a minimum or a target platelet dose. A [2024 modified Delphi consensus by Hurley and colleagues](https://iro.uiowa.edu/esploro/outputs/journalArticle/Experts-Achieve-Consensus-on-a-Majority/9984459414902771), published in Arthroscopy, states that “the ideal dose of PRP is undetermined.”

**What this means in practice:** The leukocyte-poor versus leukocyte-rich label and the 10 billion platelet figure are both unsettled. Which preparation suits which use is not settled, so choose a preparation on purpose and record it. Platelet dose is studied as one factor. In the Berrigan review, positive knee OA arms averaged about 5.5 billion platelets per injection and arms with no significant difference averaged about 2.3 billion. That is an association, not a floor or a target. Clinicians should evaluate manufacturer claims based on absolute delivered platelet dose, the leukocyte differential, and whether the system has been used in published RCTs at the same protocol the clinician will use.

Multiple classification systems exist to categorize PRP preparations, including systems based on platelet concentration, leukocyte content, activation method, and red blood cell presence. None of these systems have been validated as predictive of clinical outcomes, and this lack of standardization is one of the biggest challenges in PRP research today.

Free mini course

The FDA rules behind this field, in a short, self-paced course. It costs nothing.

[Get the free FDA course](https://regenmedacademy.com/fda-legal-foundations-of-regenerative-medicine/#free-course)

## **FDA regulatory status: what is actually cleared**

PRP preparation devices reach the market through the FDA’s 510(k) premarket notification pathway. Under this pathway, manufacturers demonstrate that their device is “substantially equivalent” to a device already on the market. This is a clearance, not an approval, and the distinction is important.

PRP preparation systems, including centrifuge kits, tubes, and separators, are cleared for producing platelet-rich preparations to be mixed with bone graft materials to enhance bone graft handling properties in orthopedic surgical procedures. Recent 510(k) clearances in 2024 confirm this limited indication. For example, OrthoAscent (BK241083) and the [Arthrex Thrombinator System (BK241060)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=BK241060) were both [cleared for bone graft handling](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=BK241083).

Injecting PRP into joints, tendons, ligaments, muscle, skin or scalp is off-label. That includes intra-articular injection for osteoarthritis, tendon injection for tendinopathy, intramuscular injection for muscle injury, and every other use outside bone graft handling. Read the 510(k) clearance for the exact system you own.

Off-label use is legal and common in medicine. Clinicians may use FDA-cleared devices off-label based on their clinical judgment. However, patients must be informed that the use is off-label, that evidence is mixed, and that outcomes are not guaranteed. Documentation of informed consent is essential.

**What this means in practice:** If you are offering or considering PRP injections for knee OA, tennis elbow, plantar fasciitis, or any other musculoskeletal condition, you are practicing off-label. This is legally permissible, but it requires transparent communication with patients about the regulatory status. Never describe PRP injections as “FDA-approved” for these indications.

## **The evidence by condition: what the research says**

The PRP evidence differs from one musculoskeletal condition to the next. Below is what named sources report for several commonly studied conditions, with their limits. Every one of these uses is off-label, and none of these findings predicts how a given patient will respond.

### **Knee osteoarthritis: what trials and societies report**

For knee OA, the trials and the societies that reviewed them do not agree.

Whether PRP does better than hyaluronic acid, corticosteroid or saline injections in knee OA is not settled. The RESTORE trial described above found no significant difference from saline at 12 months.

The [ESSKA-ORBIT Consensus](https://esskajournals.onlinelibrary.wiley.com/doi/10.1002/ksa.12077), published in 2024, issued a Grade A recommendation supporting PRP for mild-to-moderate knee OA, classified as Kellgren-Lawrence (KL) grades I through III on the standard radiographic severity scale. In randomized trials pooled by Berrigan and colleagues, the arms with a positive result averaged about 5.5 billion platelets per injection; how many individual patients respond is not settled.

However, not all professional societies agree. The [2026 ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf), approved by the American College of Rheumatology Board of Directors on September 8, 2026 and published as a summary ahead of the full papers, says: “In people with knee and hip OA, we strongly recommend against PRP treatment.” The same summary says “we strongly recommend against stem cell injections,” strongly recommends intraarticular glucocorticoid injections, and conditionally recommends against intraarticular hyaluronic acid. The 2019 ACR/Arthritis Foundation guideline said the same about PRP. The [AAOS Technology Overview (2022, literature through August 2021)](https://www.aaos.org/globalassets/quality-and-practice-resources/biologics/technology-overview_prp-for-knee-oa.pdf) makes no recommendation for or against PRP, noting substantial limitations in existing studies. The [AAOS 2021 knee OA clinical practice guideline](https://aaos.org/oak3cpg) says PRP “may reduce pain and improve function in patients with symptomatic osteoarthritis of the knee” and rates that statement limited in strength.

The following table summarizes how major professional societies have positioned themselves on PRP, mostly for knee OA. Every use in it is off-label. The Kellgren-Lawrence scale is a radiographic grading system for osteoarthritis severity, ranging from grade I (doubtful narrowing) to grade IV (severe joint space narrowing with bone-on-bone changes).

Society Year Position on PRP

ESSKA 2024 Grade A recommendation for mild-to-moderate knee OA

[AAOS clinical practice guideline](https://aaos.org/oak3cpg) (knee OA) 2021 “Platelet-rich plasma (PRP) may reduce pain and improve function in patients with symptomatic osteoarthritis of the knee.” Strength of recommendation: limited (downgraded)

AAOS Technology Overview 2022 No recommendation for or against (literature through August 2021); calls for more research

[ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf) 2026 Strongly recommends against PRP for knee and hip OA (summary approved September 8, 2026; the 2019 ACR/AF guideline said the same)

GRIIP 2025 Consensus on contraindications for patients with complex comorbidities

If a patient with mild to moderate knee OA asks about PRP, tell them what the sources say: one European consensus supports it, the 2026 ACR guideline update strongly recommends against it, a placebo-controlled trial found no difference, the use is off-label, and no one can predict whether they will respond. Shared decision-making with realistic expectations is the right approach.

### **Lateral epicondylitis: what one review summary reports**

For lateral epicondylitis, commonly known as tennis elbow, the trials are inconsistently reported, so read any summary of them with that limit in mind. Injecting PRP there is off-label.

A [2025 EFORT Open Reviews summary of orthobiologic guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC12139597/) notes a meta-analysis in which PRP for lateral epicondylitis produced improvements surpassing the minimal clinically important difference (MCID), the smallest change patients perceive as meaningful, while cautioning that the underlying trials were inconsistently reported.

### **Plantar fasciitis: what one meta-analysis reports**

Plantar fasciitis affects the thick band of tissue along the bottom of the foot. Injecting PRP there is off-label.

A [2024 meta-analysis by Herber and colleagues](https://pubmed.ncbi.nlm.nih.gov/38395675/) included 21 RCTs with 1,356 patients. PRP showed significantly greater improvement in pain scores than comparators including corticosteroids and extracorporeal shockwave therapy (ESWT). Differences on structural and functional measures were less consistent.

### **Other conditions: not settled**

For rotator cuff tendinopathy, rotator cuff repair augmentation, hamstring injuries, Achilles tendinopathy and ACL reconstruction augmentation, the evidence is not settled, and this post does not summarize it. If you are considering one of these uses, read the primary reviews yourself and note what preparation each trial used. For hip OA, the [2026 ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf) strongly recommends against PRP, as it does for the knee.

## **Understanding the contradictory evidence**

The evidence on PRP conflicts. Professional societies that reviewed overlapping bodies of literature reached opposite conclusions, as the society table above shows, and trials of the same use have reported different results.

These contradictions are not a sign that the research is broken. They reflect genuine complexity. Different studies use different PRP preparations (LP-PRP versus LR-PRP with varying platelet concentrations and leukocyte differentials), different platelet doses (often ranging from under 2 billion to over 10 billion per injection), different patient populations (varying OA severity, age, BMI), different outcome measures (VAS versus WOMAC versus condition-specific scales), and different follow-up durations. Industry-funded versus independent studies may also introduce bias. Clinicians should present both sides honestly and engage in shared decision-making with patients rather than cherry-picking only the favorable data.

## **What should a PRP consent conversation cover?**

Here is what a consent conversation for an off-label PRP injection usually covers. The device that prepares PRP is FDA cleared for use with bone graft material, and injecting PRP into a joint or tendon is off-label. The sources disagree: the ESSKA-ORBIT consensus supports PRP for mild to moderate knee OA, while the 2026 ACR guideline update strongly recommends against it for knee and hip OA and strongly recommends intraarticular glucocorticoid injections. No one can predict whether this patient will respond.

The conversation also covers soreness after the injection, the risk of infection, the alternatives and the cost. Coverage depends on the plan, so check the patient’s policy before you quote a price. Record the discussion, the preparation you used and the delivered platelet count if your system reports it.

## **Contraindications: when not to use PRP**

In 2025, the International Research Group on Platelet Injections ([GRIIP](https://pmc.ncbi.nlm.nih.gov/articles/PMC12104799/)) published a formal consensus on indications and contraindications for PRP in musculoskeletal disease in patients with infectious, oncological and hematological comorbidities. Its recommendations were rated by 31 experts from seven countries, and each carries a grade.

The consensus does not use the term “absolute contraindication.” Its statements are conditional. It advises against PRP, or advises waiting, in several situations: during antibiotic treatment of less than three months for a bacterial infection (inject “once the treatment has been completed”), in a hematologic malignancy that is under diagnosis or not stabilized, or a solid cancer that is under diagnosis or active (except in exceptional situations discussed with the hematologist or oncologist), “in the vicinity of benign or malignant tumours,” and with dental infection or an invasive oral procedure “until the completion of treatment and healing.” Read the [full GRIIP consensus text](https://orbi.uliege.be/bitstream/2268/333556/1/_Knee%20surg%20%20sports%20traumatol%20%20arthrosc%20-%202025%20-%20Eymard%20-%20Indications%20and%20contraindications%20to%20platelet%25E2%2580%2590rich%20plasma.pdf) before you rely on any one line.

Other statements set conditions. In the [GRIIP consensus](https://orbi.uliege.be/bitstream/2268/333556/1/_Knee%20surg%20%20sports%20traumatol%20%20arthrosc%20-%202025%20-%20Eymard%20-%20Indications%20and%20contraindications%20to%20platelet%25E2%2580%2590rich%20plasma.pdf), PRP may be performed in HIV infection if the viral load is undetectable and the CD4 count is above 350 per cubic millimeter (grade C). In hepatitis C it “should be performed only after antiviral treatment has been completed” (grade D). In chronic dialysis it “may be considered,” with monitoring for signs of bacteremia, and “the injection must be avoided on the day of dialysis” (grade C). With prolonged, stabilized immunosuppression it “may be performed, but particular attention must be paid to the presence of concomitant infection” (grade C). These are clinical calls for the treating clinician.

On blood counts, GRIIP says “a significant abnormality in the blood count should be investigated before PRP injection,” and that previously investigated thrombocytopenia above 50,000 per cubic millimeter, outside hematologic malignancy, “is not a contraindication to PRP injection.” Low platelet counts and recent steroid injection at the site are commonly listed as reasons to wait; your protocol and the published consensus set the details. Platelet dysfunction, hemodynamic instability and septicemia are also commonly listed. GRIIP chose not to address NSAIDs or antiplatelet drugs. There is no agreed washout period. Published protocols differ, so follow your own protocol and the prescriber, and never stop an antiplatelet drug without the prescriber.

## **Safety profile and adverse events**

PRP is prepared from the patient’s own blood. That does not make it risk-free.

Some soreness after the injection is common, and patients should hear that before the procedure. Your consent form should also cover swelling, bruising and redness at the site, and tell the patient when to call you.

Any injection into a joint carries some risk of infection, and PRP is no exception. Use strict aseptic technique, and make sure every patient knows which signs after the injection mean they should call you the same day.

Special populations require additional consideration. Diabetic patients may experience more pronounced inflammatory reactions, and blood glucose monitoring may be advisable. Patients with prosthetic joints have limited safety data, and consultation with the orthopedic team is recommended.

### **Safety reporting**

For suspected serious adverse events involving FDA-regulated medical products, devices, or drugs, clinicians can consider reporting via FDA MedWatch, consistent with institutional policy and applicable requirements.

## **What we do not know yet: evidence gaps**

Transparency about what remains unknown builds trust with patients and reflects the honest state of the science. The following are the most significant evidence gaps in PRP for musculoskeletal medicine.

No standardized preparation protocols exist across the field. Different PRP systems produce different products with different platelet concentrations, leukocyte content, and activation methods. This makes comparing results across studies extremely difficult and is the single biggest contributor to conflicting findings.

Long-term data beyond 2 years is largely absent. Most studies follow patients for 6-12 months, with a smaller number reaching 24 months. We do not know whether PRP benefits persist, diminish, or require repeat treatment cycles over longer time horizons.

The society guidance cited in this post concerns knee and hip OA. For tendons, ligaments and other uses, check whether the relevant specialty society has published a position before you rely on one.

Patient stratification remains a challenge. No validated biomarkers currently predict which patients will respond well to PRP and which will not. Platelet dose is studied as one factor, and no society names a minimum or a target dose. In knee OA, the Berrigan review found that positive arms averaged about 5.5 billion platelets and arms with no significant difference averaged about 2.3 billion, an association rather than a target. For tendons, plantar fascia and other tissues, the dose question is open.

Cost-effectiveness data is limited. Few studies have conducted rigorous economic analyses comparing PRP to alternative treatments over meaningful time periods.

The AAOS announced the [Orthobiologics Registry (OBR)](https://www.aaos.org/aaos-home/newsroom/press-releases/aaos-establishes-orthobiologics-registry-to-advance-evidence-based-orthobiologics-research/) in December 2025, a pilot program beginning with 10 participating sites specifically designed to generate the real-world evidence that is currently lacking. This registry aims to address preparation standardization, long-term outcomes, and patient selection questions.

**What this means in practice:** When patients ask whether PRP “works,” tell them what the named sources found, that the sources disagree, and that important questions remain unanswered. Clinicians who offer PRP should frame it as an evolving, off-label field, not an established standard of care.

## **Which patients do the studies and guidelines describe?**

Studies and guidelines describe the patients they included. They do not tell you which of your patients will respond, and every use below is off-label.

The ESSKA-ORBIT consensus and the RESTORE trial both concern mild to moderate knee OA, and they point in opposite directions; the 2026 ACR guideline update strongly recommends against PRP for knee and hip OA. The Herber meta-analysis pooled trials in plantar fasciitis. The EFORT summary describes the lateral epicondylitis trials as inconsistently reported.

For severe knee OA and for the rotator cuff, hamstring, Achilles tendon and ACL, this post does not summarize the evidence because it is not settled. PRP is not a substitute for surgical intervention when surgery is clearly indicated.

Response rates vary. Not every patient will experience meaningful improvement, and individual outcomes cannot be predicted or guaranteed. Clinicians should set expectations using population-level data while emphasizing that individual response depends on many factors, including disease severity, preparation method, platelet dose, injection technique, and patient biology.

## **Frequently asked questions**

### **Is PRP FDA-approved for joint injections?**

No. PRP preparation devices are FDA-cleared under the 510(k) pathway for bone graft handling only. All injection applications for joints, tendons, and soft tissue are considered off-label. Off-label use is legal, but patients must be informed of this status.

### **How many PRP injections are typically needed?**

Protocols vary, and no number of injections or interval has been shown to be optimal. Follow your own protocol, and record the number of injections, the interval and the preparation for each patient.

### **How long do PRP results last?**

No one can tell a patient how long an effect will last, or whether there will be one. Most of the knee OA results cited in this post are reported at 6 or 12 months, and long-term data are limited. Individual results vary and are not guaranteed.

### **Is PRP painful?**

Some soreness after the injection is common, and patients should hear that before the procedure. Your consent form should also cover swelling and the signs that mean the patient should call you. Any injection into a joint carries some risk of infection, and PRP is no exception.

### **Does insurance cover PRP injections?**

Coverage depends on the plan. Check each patient’s policy before you quote a price, and take coverage questions to the payer and your biller. For Medicare, when we checked on November 4, 2026, the [national coverage determination for blood-derived products (NCD 270.3)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=217), in its version effective April 13, 2021, said CMS “will cover autologous PRP for the treatment of chronic non-healing diabetic wounds” for 20 weeks under set conditions. It does not address musculoskeletal use.

### **Which PRP preparation is best?**

Which preparation suits which use is not settled. Consensus statements and trials do not agree on one answer, so choose a preparation on purpose and record it. In the Di Martino trial cited above, leukocyte-poor and leukocyte-rich PRP showed no significant difference in knee OA at 12 months. Platelet dose is studied as one factor too, and no society names a minimum or a target dose.

### **Is there a minimum platelet dose for PRP?**

No professional society names a minimum or a target dose. In the Berrigan review of knee OA trials, positive arms averaged about 5.5 billion platelets per injection and arms with no significant difference averaged about 2.3 billion. That is an association across trials, not a proven dose effect. The often quoted 10 billion figure traces to a single 2021 trial (Bansal and colleagues) that tested one dose level, and it is not a settled standard. Record the delivered platelet dose if your system reports it.

### **Can PRP replace surgery?**

PRP should not be presented as a replacement for surgery when surgical intervention is clearly indicated. Some patients may use PRP as part of a conservative management strategy before considering surgery, or as an adjunct to surgical procedures, but this decision should be individualized based on clinical assessment.

### **Should patients stop taking NSAIDs before PRP?**

There is no agreed washout period. Published protocols differ, so follow your own protocol and the prescriber, and never stop an antiplatelet drug without the prescriber. The 2025 GRIIP consensus chose not to address NSAIDs or antiplatelet drugs.

## **Key takeaways**

- PRP devices are FDA-cleared for bone graft handling only. All musculoskeletal injection applications are off-label and require informed consent disclosure.
- The evidence differs by condition and the sources disagree. Report what a named source found, with its limits, rather than ranking conditions.
- Professional societies disagree on knee OA: ESSKA-ORBIT supports PRP (Grade A), the 2026 ACR guideline update strongly recommends against it for knee and hip OA, the AAOS 2021 guideline rates its supportive statement limited in strength, and the AAOS Technology Overview makes no recommendation either way.
- Which preparation suits which use is not settled. Consensus statements and trials do not agree on one answer, so choose a preparation on purpose and record it.
- Platelet dose is studied as one factor, and no society names a minimum or a target. In the Berrigan review, positive knee OA arms averaged about 5.5 billion platelets and arms with no significant difference averaged about 2.3 billion. The “10 billion threshold” claim derives from a single 2021 RCT, not a settled standard.
- Preparation variability (LP-PRP versus LR-PRP, different platelet doses, different activation methods) is the primary driver of conflicting research findings.
- Individual results vary and cannot be guaranteed; a meaningful share of patients do not respond.
- The 2025 GRIIP consensus advises against PRP, or advises waiting, in several situations, including bacterial infection under treatment, hematologic malignancy that is not stabilized and solid cancer that is active or under diagnosis, with exceptions discussed with the specialist.
- If you are considering adding PRP, [hands-on musculoskeletal orthobiologic training](https://regenmedacademy.com/musculoskeletal-courses/) gives you supervised cases and a method. It does not guarantee a clinical result.

## **Adding PRP to your practice**

PRP is a technique where the literature alone cannot teach you what you need to know. Preparation system selection, dosing calibration, neutrophil-aware processing, ultrasound-guided injection technique, and informed consent documentation all require practical skill that develops through supervised, hands-on instruction. Reading the evidence is half of it. Technique, patient selection and documentation are learned under supervision. RMA’s [regenerative medicine training courses](https://regenmedacademy.com/our-courses/) are designed for licensed clinicians who want to translate the evidence reviewed in this article into reproducible bedside practice.

Or skip the catalog and [talk to us](https://regenmedacademy.com/contact/).

## **About Regenerative Medicine Academy**

Regenerative Medicine Academy (RMA) is a medical education company providing hands-on, private regenerative medicine training courses for licensed healthcare professionals. RMA does not provide clinical treatments or medical services. All course content is educational and designed to support clinicians in making informed, evidence-based decisions within their scope of practice. For more information about courses and [online regenerative medicine education](https://regenmedacademy.com/e-courses/), visit regenmedacademy.com.

If the evidence picture here maps to the patients you already see, the next step is technique. [The PRP training pathway](https://regenmedacademy.com/prp-training/) covers preparation, guidance, and live-patient practice, and [the full catalog](https://regenmedacademy.com/our-courses/) shows where each course fits.

## **Off-label use note**

Every PRP injection use in this article is an off-label use of a device that FDA cleared for use with bone graft material. Off-label means FDA has not cleared the device for the described use. Clinicians may use FDA-cleared devices off-label in their clinical judgment, but must obtain informed consent, discuss evidence, risks, and alternatives, and document thoroughly.

## **Platform/jurisdiction note**

Scope of practice, supervision requirements, and corporate practice of medicine rules vary by state. Clinicians should consult their state medical board, malpractice carrier, and legal counsel regarding compliance in their jurisdiction before offering regenerative procedures.

The course that goes with this post

## Introduction to PRP for Musculoskeletal Injuries

The foundation course: platelet biology, whole blood handling, spin protocols and injection technique, hands on with a supervised consenting patient.

Starting at $5,000 at an instructor’s clinic, or $10,000 inside your practice.

[See the course](https://regenmedacademy.com/introduction-to-platelet-rich-plasma-prp-therapy-for-musculoskeletal-injuries/)

[Request a date now](https://regenmedacademy.com/contact/?course=intro-prp-msk)

[Or see all courses](https://regenmedacademy.com/our-courses/)

## Important information

### Education, not medical advice

Regen Med Academy provides education and training for licensed healthcare providers. Everything on this site is for educational purposes only. It is not medical advice, not a treatment recommendation, and not an offer to treat. Providers are responsible for practicing within the scope of their own license and their own state law.

### Where a course can run

Courses are taught only in states where the modality is legal for the license you hold. State law in this field changes, sometimes more than once a year. Our reading of each state, with its sources and the date we checked, is on the [rules by state page](/regenerative-medicine-laws-by-state/). It is a starting point, not legal advice. It is your responsibility to confirm the modality is legal in your state for your license. Do that before you book. The authority on your own scope is your licensing board, not us. State medical board contact details are published by the [Federation of State Medical Boards](https://www.fsmb.org/contact-a-state-medical-board/).

### Training on live patients

Procedures performed during training are performed on consenting patients, by licensed providers, under supervision. Participation is voluntary and outcomes vary.

### Products and modalities

Some products and modalities discussed in these courses are not FDA approved or cleared for the uses described. Regen Med Academy does not manufacture, sell or endorse any product, and does not approve or clear any product. The FDA publishes guidance for patients and providers on [regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies).

### What a certificate is, and is not

Regen Med Academy does not offer CMEs, credit hours or accreditation of any kind. What you receive is a Certificate of Completion. It records that you attended and performed the procedures under supervision. It is not a license, not a board certification, and it does not expand your scope of practice.

### Coverage is yours to arrange

You are responsible for your own malpractice coverage. We will help you work out what to ask your carrier, and we recommend getting the answer in writing. Regen Med Academy does not provide, arrange or extend coverage to trainees, and nothing on this page is legal advice or an assurance of coverage.

[NextPRP vs corticosteroid injections: what the evidence shows for musculoskeletal careNext](https://regenmedacademy.com/prp-vs-corticosteroid-injections-the-evidence/)

#### Table of Contents

Prefer our take? Star us in Google.

## More from the blog

[Nov 4, 2026By Oscar Tellez ### 351 or 361: which rule covers the product in my clinic? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/351-vs-361-hctp-rules/)[Nov 3, 2026By Oscar Tellez ### Who on my staff can draw, spin and inject PRP? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/who-can-draw-spin-and-inject-prp/)[Nov 2, 2026By Oscar Tellez ### How do I get trained in PRP injections as a nurse practitioner? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/prp-training-for-nurse-practitioners/)

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/regenmedacademy.com\/#organization","name":"Regen Med Academy","sameAs":["https:\/\/www.facebook.com\/regenmedacademy\/","https:\/\/www.instagram.com\/regenmedacademy\/","https:\/\/www.linkedin.com\/company\/regenerative-medicine-academy-usa\/"],"logo":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/#logo","url":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","contentUrl":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","caption":"Regen Med Academy","inLanguage":"en-US","width":"964","height":"160"}},{"@type":"WebSite","@id":"https:\/\/regenmedacademy.com\/#website","url":"https:\/\/regenmedacademy.com","name":"Regen Med Academy","alternateName":"Regenerative Medicine Academy","publisher":{"@id":"https:\/\/regenmedacademy.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-therapy-for-musculoskeletal-injuries_-what-every-clinician-should-know-r3.webp","url":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-therapy-for-musculoskeletal-injuries_-what-every-clinician-should-know-r3.webp","width":"1024","height":"1024","caption":"Clinician in blue gloves performs an ultrasound-guided knee injection with a syringe of platelet-rich plasma, ultrasound image visible on the monitor behind","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/regenmedacademy.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/regenmedacademy.com\/our-blogs\/","name":"Blogs"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/regenmedacademy.com\/category\/prp\/","name":"PRP"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/","name":"PRP therapy for musculoskeletal injuries: what every clinician should know"}}]},{"@type":"WebPage","@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#webpage","url":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/","name":"PRP Therapy For Musculoskeletal Injuries: A Primer","datePublished":"2026-06-01T10:45:00-04:00","dateModified":"2026-11-04T12:14:25-05:00","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-therapy-for-musculoskeletal-injuries_-what-every-clinician-should-know-r3.webp"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#breadcrumb"}},{"@type":"Person","@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez","url":"https:\/\/regenmedacademy.com\/oscar-tellez\/","image":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","url":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","caption":"Oscar Tellez","inLanguage":"en-US"},"sameAs":["https:\/\/regenmedacademy.com\/oscar-tellez\/"],"worksFor":{"@id":"https:\/\/regenmedacademy.com\/#organization"}},{"@type":"BlogPosting","headline":"PRP Therapy For Musculoskeletal Injuries: A Primer","keywords":"prp","datePublished":"2026-06-01T10:45:00-04:00","dateModified":"2026-11-04T12:14:25-05:00","articleSection":"PRP","author":{"@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez"},"publisher":{"@id":"https:\/\/regenmedacademy.com\/#organization"},"description":"A clinical primer on PRP in musculoskeletal care. Preparation variables, injection targets, the evidence base and where the open questions still sit.","name":"PRP Therapy For Musculoskeletal Injuries: A Primer","@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#richSnippet","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#webpage"},"image":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-therapy-for-musculoskeletal-injuries_-what-every-clinician-should-know-r3.webp"},"inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#webpage"}}]},{"@context":"https:\/\/schema.org","@type":"FAQPage","@id":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/#faq","url":"https:\/\/regenmedacademy.com\/prp-therapy-for-musculoskeletal-injuries\/","mainEntity":[{"@type":"Question","name":"Is PRP FDA-approved for joint injections?","acceptedAnswer":{"@type":"Answer","text":"No. PRP preparation devices are FDA-cleared under the 510(k) pathway for bone graft handling only. All injection applications for joints, tendons, and soft tissue are considered off-label. Off-label use is legal, but patients must be informed of this status."}},{"@type":"Question","name":"How many PRP injections are typically needed?","acceptedAnswer":{"@type":"Answer","text":"Protocols vary, and no number of injections or interval has been shown to be optimal. Follow your own protocol, and record the number of injections, the interval and the preparation for each patient."}},{"@type":"Question","name":"How long do PRP results last?","acceptedAnswer":{"@type":"Answer","text":"No one can tell a patient how long an effect will last, or whether there will be one. Most of the knee OA results cited in this post are reported at 6 or 12 months, and long-term data are limited. Individual results vary and are not guaranteed."}},{"@type":"Question","name":"Is PRP painful?","acceptedAnswer":{"@type":"Answer","text":"Some soreness after the injection is common, and patients should hear that before the procedure. Your consent form should also cover swelling and the signs that mean the patient should call you. Any injection into a joint carries some risk of infection, and PRP is no exception."}},{"@type":"Question","name":"Does insurance cover PRP injections?","acceptedAnswer":{"@type":"Answer","text":"Coverage depends on the plan. Check each patient\u2019s policy before you quote a price, and take coverage questions to the payer and your biller. For Medicare, when we checked on November 4, 2026, the national coverage determination for blood-derived products (NCD 270.3), in its version effective April 13, 2021, said CMS \u201cwill cover autologous PRP for the treatment of chronic non-healing diabetic wounds\u201d for 20 weeks under set conditions. It does not address musculoskeletal use."}},{"@type":"Question","name":"Which PRP preparation is best?","acceptedAnswer":{"@type":"Answer","text":"Which preparation suits which use is not settled. Consensus statements and trials do not agree on one answer, so choose a preparation on purpose and record it. In the Di Martino trial cited above, leukocyte-poor and leukocyte-rich PRP showed no significant difference in knee OA at 12 months. Platelet dose is studied as one factor too, and no society names a minimum or a target dose."}},{"@type":"Question","name":"Is there a minimum platelet dose for PRP?","acceptedAnswer":{"@type":"Answer","text":"No professional society names a minimum or a target dose. In the Berrigan review of knee OA trials, positive arms averaged about 5.5 billion platelets per injection and arms with no significant difference averaged about 2.3 billion. That is an association across trials, not a proven dose effect. The often quoted 10 billion figure traces to a single 2021 trial (Bansal and colleagues) that tested one dose level, and it is not a settled standard. Record the delivered platelet dose if your system reports it."}},{"@type":"Question","name":"Can PRP replace surgery?","acceptedAnswer":{"@type":"Answer","text":"PRP should not be presented as a replacement for surgery when surgical intervention is clearly indicated. Some patients may use PRP as part of a conservative management strategy before considering surgery, or as an adjunct to surgical procedures, but this decision should be individualized based on clinical assessment."}},{"@type":"Question","name":"Should patients stop taking NSAIDs before PRP?","acceptedAnswer":{"@type":"Answer","text":"There is no agreed washout period. Published protocols differ, so follow your own protocol and the prescriber, and never stop an antiplatelet drug without the prescriber. The 2025 GRIIP consensus chose not to address NSAIDs or antiplatelet drugs."}}]}]
```